Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation

NCT01206101 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01206101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01206101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2012
Completion date
June 3, 2013
Enrollment
3 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1